Tianben Biological

Shanghai Tianben Biological Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative cell therapies for cancer. The company focuses on engineering next-generation CAR-T and TCR-T products designed to address the limitations of current immunotherapies, particularly in solid tumors. Their lead candidate, TB001, is a dual-target CAR-T therapy for B-cell malignancies, while other programs target Glypican-3 and Mesothelin for liver and pancreatic cancers. Tianben operates its own R&D center and GMP-compliant manufacturing facility to ensure high-quality production of cell products. By integrating advanced genetic engineering with clinical insights, the company aims to provide curative treatments for patients with refractory or relapsed malignancies.